The dental and medicinal benefits board, TLV, has decided on 19 October that ORGOVYX® , tablets for the treatment of advanced hormone-sensitive prostate cancer in Sweden, should be included in the pharmaceutical benefit scheme from 2023-10-

Accord Healthcare Denmark Sweden Finland Norway

TLV assesses the severity of advanced hormone-sensitive prostate cancer as high1.The condition is progressive and carries a risk of developing metastatic castration-resistant prostate cancer (mCRPC), which is associated with a greatly shortened lifespan and reduced quality of life1.Orgovyx is the first castration treatment in the form of a tablet, which means that patients avoid injection-related side effects that are the case with today's treatments and that it frees up time for the health care2,1.View original content:https://www.prnewswire.co.uk/news-releases/the-dental-and-medicinal-benefits-board-tlv-has-decided-on-19-october-that-orgovyx-relugolix-tablets-for-the-treatment-of-advanced-hormone-sensitive-prostate-cancer-in-sweden-should-be-included-in-the-pharmaceutical-benefit-301964940.html